Objectives: Laboratory studies suggest elevated blood pressure after resuscitation from cardiac arrest may be protective; however, clinical data are limited. We sought to test the hypothesis that elevated postresuscitation mean arterial blood pressure is associated with neurologic outcome. Design: Preplanned analysis of a prospective cohort study. Setting: Six academic hospitals in the United States. Patients: Adult, nontraumatic cardiac arrest patients treated with targeted temperature management after return of spontaneous circulation. Interventions: Mean arterial blood pressure was measured noninvasively after return of spontaneous circulation and every hour during the initial 6 hours after return of spontaneous circulation. Measures and Main Results: We calculated the mean arterial blood pressure and a priori dichotomized subjects into two groups: mean arterial blood pressure 70-90 and greater than 90 mm Hg. The primary outcome was good neurologic function, defined as a modified Rankin Scale less than or equal to 3. The modified Rankin Scale was prospectively determined at hospital discharge. Of the 269 patients included, 159 (59%) had a mean arterial blood pressure greater than 90 mm Hg. Good neurologic function at hospital discharge occurred in 30% of patients in the entire cohort and was significantly higher in patients with a mean arterial blood pressure greater than 90 mm Hg (42%) as compared with mean arterial blood pressure 70-90 mm Hg (15%) (absolute risk difference, 27%; 95% CI, 17-37%). In a multivariable Poisson regression model adjusting for potential confounders, mean arterial blood pressure greater than 90 mm Hg was associated with good neurologic function (adjusted relative risk, 2.46; 95% CI; 2.09-2.88). Over ascending ranges of mean arterial blood pressure, there was a dose-response increase in probability of good neurologic outcome, with mean arterial blood pressure greater than 110 mm Hg having the strongest association (adjusted relative risk, 2.97; 95% CI, 1.86-4.76). Conclusions: Elevated blood pressure during the initial 6 hours after resuscitation from cardiac arrest was independently associated with good neurologic function at hospital discharge. Further investigation is warranted to determine if targeting an elevated mean arterial blood pressure would improve neurologic outcome after cardiac arrest. (Crit Care Med 2019; 47:93-100) Key Words: blood pressure; cardiac arrest; heart arrest; resuscitation C ardiac arrest occurs in over 400,000 people each year in the United States alone (1) . Even among those who attain return of spontaneous circulation (ROSC) after cardiac arrest, in-hospital mortality remains over 50%, with a large proportion of survivors experiencing permanent and severe neurologic disability (2) . After ROSC there is ongoing cerebral injury secondary to oxidant damage (3, 4) . Thus, finding new approaches to attenuate brain injury after resuscitation is a high priority for resuscitation science.
Brain injury secondary to cardiac arrest can result in disruption of normal cerebrovascular autoregulation (5, 6) . As a result, cerebral blood flow may become directly related to cerebral perfusion pressure (6) . Thus, an elevated mean arterial blood pressure (MAP) after resuscitation from cardiac arrest could improve cerebral blood flow through increased cerebral perfusion pressure, potentially attenuating ongoing cerebral injury. Current postcardiac arrest guidelines recommend avoiding and immediately correcting postresuscitation hypotension (7, 8) . However, there is currently insufficient evidence to recommend a specific blood pressure target. Our group previously published a single-center prospective cohort study demonstrating an association between postresuscitation MAP less than 70 mm Hg and poor neurologic outcome at hospital discharge (9) . However, secondary to sample size limitations we were unable to adequately test whether higher MAPs were associated with improved neurologic outcome.
In this multicenter cohort study, our main objective was to test the association between elevated postresuscitation MAP and neurologic outcome among adult patients successfully resuscitated from cardiac arrest.
METHODS

Setting
We performed a preplanned analysis of a prospective cohort study across six hospitals in the United States. We prospectively compiled and maintained an Utstein style cardiac arrest registry (10, 11) . The Institutional Review Board at each participating institution approved this study. This study is reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology Statement (12) .
Participants
Adult postcardiac arrest patients who were comatose after ROSC between July 2013 and March 2017 were included. The inclusion criteria were 1) age greater than or equal to 18 years; 2) cardiac arrest, defined as a documented absence of pulse and the initiation of cardiopulmonary resuscitation (CPR); 3) ROSC greater than 20 minutes; 4) unresponsive (i.e., Glasgow Coma Score motor < 6) and mechanical ventilation after ROSC; and 5) clinician intent to perform targeted temperature management. We included patients with both in-and out-of-hospital cardiac arrest in order to allow for a pragmatic study from which results could be broadly applicable to as many cardiac arrest patients as possible. We excluded subjects with presumed etiology of arrest secondary to trauma, hemorrhage, or sepsis; residents of a nursing home or other long-term care facility; pregnancy; prisoners; and known lack of commitment to aggressive support by next of kin. We excluded patients with persistent hypotension during the initial 6 hours after ROSC (defined as mean postresuscitation MAP < 70 mm Hg) (9) . We excluded these patients on the grounds that it has already been demonstrated that hypotension is associated with worse outcomes (2, 9, 13, 14) . Excluding these patients would permit us to focus the analysis on the association between elevations in MAP and neurologic outcome.
Data Collection
As part of our research protocol, we measured MAP immediately after ROSC and hourly thereafter using a noninvasive blood pressure cuff for the first 6 hours after ROSC. We calculated the MAP over the initial 6 hours after ROSC. We chose the initial 6 hours as our time frame as it has previously been demonstrated to be the most critical time period for hemodynamic optimization after cardiac arrest (15) . We prospectively captured all the components of the Sequential Organ Failure Assessment (SOFA) score (i.e., respiratory, coagulation, hepatic, renal, cardiovascular, and neurologic) during the first 6 hours after ROSC to assess severity of illness (16) . For calculation of the total SOFA score, we excluded the neurologic component as described previously (16) (17) (18) , as well as the cardiovascular component given collinearity with MAP. We prospectively captured vasopressor administration during the first 6 hours after ROSC and used the SOFA cardiovascular score to quantify vasopressor dosing. We abstracted clinical data from the medical record into Research Electronic Data Capture (Vanderbilt University, TN), a secure, internet-based application designed to support data capture for research studies (19) and exported into Stata/SE 14.1 for Mac, StataCorp LP (College Station, TX).
Outcome Measures
The primary outcome was good neurologic function at hospital discharge, a priori defined as a modified Rankin Scale (mRS) less than or equal to 3 (20, 21) . The mRS was prospectively determined as part of our research protocol for each patient at the time of hospital discharge. All raters were trained and certified in mRS assessment (22) and used a structured questionnaire and interview, which have been shown to produce strong interobserver reliability (23, 24) . Secondary outcomes were survival to hospital discharge and good early neurologic response, defined a priori as a Full Outline of UnResponsiveness (FOUR) score greater than 6 at 72 hours after ROSC, based on previous literature (25, 26) .
Data Analysis
We began the analysis with descriptive statistics. We displayed categorical data as counts and proportions, and continuous data as mean values and sd or median values and interquartile range (IQR), based on distribution of data. Continuous variables were compared using Student t test or Wilcoxon ranksum test, based on the distribution of the data and categorical variables were compared using the chi-square test.
For our primary analysis, we a priori grouped subjects into two categories: MAP 70-90 and greater than 90 mm Hg, based on previous literature (15) . For the primary outcome, we calculated relative risks (RRs) using multivariable Poisson regression (27) . We entered candidate variables that were previously demonstrated to be strong predictors of poor outcome in postcardiac arrest patients into the model (for full description of the model, see Supplemental Methods, Supplemental Digital Content 1, http://links.lww.com/CCM/E94). The same analyses were performed for the secondary outcomes.
For the primary outcome, we performed multiple preplanned subgroup analyses. We also tested if the dose of vasopressor administration modified the association between MAP and neurologic outcome, as well as tested for a doseresponse between incremental increases in MAP and neurologic outcome (detailed description of sensitivity analyses is discussed in Supplemental Methods, Supplemental Digital Content 1, http://links.lww.com/CCM/E94). Finally, we performed two post hoc sensitivity analyses: 1) we tested the association between the duration of exposure to MAP greater than 90 mm Hg and neurologic outcome and 2) we tested the primary analysis among only patients who survived to hospital discharge. All models used robust se and allowed for intragroup correlations at the institution (i.e., site of enrollment) level.
RESULTS
Our prospective cohort consisted of 280 subjects (study flow diagram previous published) (28) . Eleven subjects (4%) were excluded for a MAP less than 70 mm Hg leaving 269 subjects in the final cohort. The mean (sd) MAP was 95 (15) mm Hg for the entire cohort and 101 (14) and 93 (15) mm Hg for subjects with and without good neurologic outcome at hospital discharge, respectively (p < 0.001 using Student t test). Onehundred fifty-nine subjects (59%) had a MAP greater than 90 mm Hg during the initial 6 hours after ROSC. Eighty-two subjects (30%) were found to have the primary outcome of good neurologic function at hospital discharge among the entire cohort. Among subjects with a MAP 70-90 mm Hg, good neurologic outcome was observed for 15% compared with 42% among those with a MAP greater than 90 (absolute risk difference, 27%; 95% CI, 17-37%; p < 0.001). The proportion of subjects with each mRS score stratified by MAP is displayed in Figure 1 .
In total, 218 subjects survived to 72 hours and 81 (74%) versus 137 (86%) survived to 72 hours among patients with a MAP 70-90 and greater than 90 mm Hg, respectively (p = 0.01). Among the entire cohort that survived to 72 hours, the median (IQR) FOUR score was 8 (3-13). Patients with a MAP greater than 90 mm Hg had a higher median (IQR) FOUR score compared with patients with a MAP 70-90 (11 [5] [6] [7] [8] [9] [10] [11] [12] [13] vs 6 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] ; p < 0.001 using Wilcoxon rank-sum test), as well as a higher proportion of good early neurologic response (66% vs 49%; absolute risk difference, 17%; 95% CI, 4-30%; p = 0.013) One-hundred twenty-two subjects survived to hospital discharge. Compared with a MAP 70-90 mm Hg, a MAP greater than 90 mm Hg was associated with increased survival to hospital discharge (28% vs 57%; absolute risk difference, 29%; 95% CI, 18-40%; p < 0.001). Survival to hospital discharge among patients with and without good early neurologic response was 80% versus 18%, respectively (absolute risk difference, 62%; 95% CI, 51-72%; p < 0.001). Of note, a higher proportion of patients with a MAP 70-90 mm Hg had withdraw of lifesustaining therapy during hospitalization compared with MAP greater than 90 mm Hg (58% vs 35%, respectively; p < 0.001). Table 2 displays the results of the multivariable Poisson regression models for the primary and secondary outcomes. After adjusting for potential confounders, a MAP greater than 90 mm Hg was an independent predictor of good neurologic function at hospital discharge (RR, 2.46; 95% CI, 2.09-2.88; p < 0.001), as well as survival to hospital discharge and early neurologic response (for full results of all regression models, see Supplemental Tables 2-4 between MAP greater than 90 mm Hg and good neurologic outcome was found to be stronger among subjects with a previous diagnosis of hypertension compared with those without hypertension (RR, 4.95; 95% CI, 2.18-11.26 vs 1.28; 95% CI, 1.13-1.46, respectively).
We did not find evidence that the association between MAP greater than 90 mm Hg and good neurologic outcome differed as vasopressor dose increased (Supplemental Table  5 , Supplemental Digital Content 1, http://links.lww.com/ CCM/E94). Figure 3 displays the proportion of good neurologic outcome across ascending ranges of MAP. Entering MAP as a categorical variable into the original model we found a dose-response increase in the probability of good neurologic outcome among all MAP ranges above 90 mm Hg compared with the reference range of postresuscitation MAP 70-80 mm Hg (Supplemental Table 6 , Supplemental Digital Content 1, http://links.lww.com/CCM/E94). MAP greater than 110 mm Hg had the strongest association with good neurologic outcome at hospital discharge (adjusted RR, 2.97; 95% CI, 1.86-4.76; p ≤ 0.001). We also found for every additional hourly blood pressure measurement with MAP greater than 90 mm Hg there was a 15% increase in the probability of good neurologic outcome (adjusted RR, 1.15; 95% CI, 1.11-1.18; p < 0.001) (Supplemental Table 7 , Supplemental Digital Content 1, http://links.lww.com/CCM/E94). Among patients who survived to hospital discharge, 67% had good neurologic outcome at hospital discharge. MAP greater than 90 mm Hg remained an independent predictor of good neurologic outcome among survivors to hospital discharge (RR, 1.36; 95% CI, 1.08-1.72) (Supplemental Table 8 , Supplemental Digital Content 1, http://links.lww.com/CCM/E94).
DISCUSSION
In this multicenter prospectively compiled cohort, we tested the association between elevated MAP after resuscitation from cardiac arrest and neurologic outcome. By excluding patients with persistent hypotension, we were able to test if the association between arterial blood pressure and neurologic outcome was driven by exposure to higher arterial blood pressure as opposed to exposure to arterial hypotension. In this cohort, 59% of patients had a MAP greater than 90 mm Hg during the initial 6 hours after ROSC. Compared with a MAP 70-90 mm (7) 11 (10) 7 (4) 0.071
Renal insufficiency 41 (15) 19 (17) 22 (14) 0.441
Pulmonary disease 63 (23) 28 (25) 35 (22) 0.512
Cerebral vascular disease 24 (9) 12 (11) 12 (8) 0.342
Congestive heart failure 68 (25) 35 (32) 33 (21) 0.040
Charlson Comorbidity Score, median (IQR)
Arrest location, n (%)
Out-of-hospital 209 (78) 78 (71) 131 (82) In-hospital 60 (22) 32 (29) 28 (18) Hg, a MAP greater than 90 mm Hg was independently associated with good neurologic outcome at hospital discharge. Our results suggest a dose-response association between duration of exposure to MAP greater than 90 mm Hg and good neurologic outcome, as well as higher MAPs and good neurologic outcome, with postresuscitation MAP greater than 110 mm Hg having the strongest association. In addition, we found an elevated MAP to be associated with good early neurologic response as well as survival to hospital discharge. Good early neurologic response was associated with survival to hospital discharge, suggesting that neurologic injury was a major factor for mortality. Thus, it is reasonable to infer that the association between postresuscitation MAP and mortality is mediated by early neurologic injury. In summary, in this prospective, multicenter cohort, we found that elevated MAP during the early period after ROSC is associated with good neurologic outcome.
In subgroup analyses, we found the relationship between MAP greater than 90 mm Hg and good neurologic outcome was similar regardless of location of arrest, initial rhythm, or administration of vasopressor agent. Of note, we found the association between MAP greater than 90 mm Hg and good neurologic outcome was stronger among subjects with a previous diagnosis of hypertension compared with among those without hypertension. The stronger association among subjects with a history of chronic hypertension may suggest an underlying shift in the cerebral autoregulation curve resulting in these patients requiring a higher MAP to maintain adequate cerebral blood flow at baseline (29, 30) . Thus, patients with a Figure 1 . Modified Rankin Scale (mRS) at hospital discharge stratified by mean arterial blood pressure (MAP) 70-90 mm Hg (gray columns) and MAP greater than 90 mm Hg (black columns). mRS: 0, no symptoms; 1, no significant disability; 2, slight disability; 3, moderate disability; 4, moderate severe disability; 5, severe disability; 6, death. history of hypertension may be more susceptible to additional brain injury when exposed to lower arterial blood pressure. These findings suggest that the optimal MAP may be patient dependent and that some patients may benefit from MAPs higher than the current recommendation of maintaining MAP greater than 65 mm Hg (7) . During the early post-ROSC period, shifts in arterial blood pressure could potentially put patients at risk for additional brain injury, and thus maintenance of an elevated MAP during this time may improve cerebral blood flow and confer neuroprotection. This hypothesis is supported by animal models, in which an induced hypertensive surge attenuates brain injury and improves outcomes (31) (32) (33) (34) . Our group previously performed a single-center prospective cohort study examining the association between elevated MAP and neurologic outcome (9) . We found that a MAP less than 70 mm Hg is associated with poor neurologic outcome. Although we did not observe an association with increasing MAPs above 90 mm Hg and improved neurologic outcome, this study was limited by a single-center design, inclusion of only 12 patients with a MAP greater than 100 mm Hg, and inconsistent use of targeted temperature management.
This current investigation has several advantages over previous studies that advance this area of investigation. First, we prospectively collected MAP measurements and vasopressor utilization over the initial 6 hours after ROSC. Additionally, we obtained protocol directed assessments of neurologic disability in real time, as opposed to abstracting this information through chart review. Furthermore, all subjects received consistent guideline-driven postcardiac arrest care including targeted temperature management. Second, this study represented a larger multicenter population, with the majority of patients exhibiting a postresuscitation MAP greater than 90 mm Hg. In addition, we excluded patients with persistent postresuscitation hypotension from our analyses to ensure our results were driven by elevated blood pressure as opposed to exposure to hypotension.
We acknowledge that this study has important limitations to consider. First, this was an observational study, and thus we can only report association rather than infer causation. It is possible that postresuscitation MAP greater than 90 mm Hg reflects a patient population that is less ill in general and therefore has a higher likelihood to have good neurologic outcome. However, we did not observe any significant differences in the postresuscitation SOFA score, alveolar plateau pressure, or rate of postresuscitation percutaneous coronary intervention or hypoxia between the two groups, suggesting this was not the case. Compared with patients with a MAP greater than 90 mm Hg, we found patients with a MAP 70-90 mm Hg were less likely to have good early neurologic response, as well as more likely to have withdraw of life-sustaining therapy. However, we are unable to determine if lower MAP causes early neurologic injury leading to withdraw of care, or if lower MAP is a marker for severity of illness influencing clinician decision to withdraw care. However, we found the association between MAP greater than 90 mm Hg and good neurologic outcome at hospital discharge remained statistically significant when limited to subjects who survived to hospital discharge, suggesting that the decision to withdraw life-sustaining therapy did not confound our results. Although we did observe patients with a MAP of 70-90 mm Hg had a longer duration of CPR compared with patients with a MAP greater than 90 mm Hg, after adjusting all of our models for duration of CPR, MAP greater than 90 mm Hg remained an independent predictor of good neurologic outcome. Second, although we prospectively recorded MAP at least every hour, we did not require invasive blood pressure monitoring. However, the noninvasive blood pressure (cuff) measurement technique is accurate and ubiquitous in routine clinical practice. Thus, our results are generalizable. Third, although all our clinicians aim to prevent exposure to hypotension as per current postcardiac arrest guidelines (7, 8) , given there is equipoise as to the optimal target MAP, our protocol did not involve a standardized blood pressure target. Thus, blood pressure goals varied between treating clinicians. Of note, among patients with a MAP greater than 90 mm Hg who were on vasopressors, 25 of 59 (42%) had exposure to hypotension during the initial 6 hours after ROSC. Thus, among these 25 patients, it is possible that the higher MAPs were the result of a rebound in blood pressure while attempting to treat hypotension. However, it is likely that the remaining patients with higher MAPs who received vasopressors did so as a result of clinicians specifically targeting higher MAPs. Fourth, although we used multivariable Poisson regression analyses to adjust for cardiac arrest characteristics known to predict poor outcomes, there exists the potential of unmeasured confounders. Fifth, although we prospectively recorded administration of vasopressor infusion and quantified the administered dose using the cardiovascular component of the SOFA score we did not collect data on number of vasopressor agents administered.
CONCLUSIONS
MAP greater than 90 mm Hg during the initial 6 hours after ROSC is associated with good neurologic outcome at hospital discharge. This association was strongest among patients with a history of chronic hypertension, suggesting the association between arterial blood pressure and neurologic outcome may be patient dependent. Further investigation is warranted to determine if interventions targeting an elevated arterial blood pressure would improve neurologic outcome after cardiac arrest and which patient populations may benefit.
